2021
Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis—A Systematic Review and Meta-Analysis
Bewersdorf JP, Sheth AH, Vetsa S, Grimshaw A, Giri S, Podoltsev NA, Gowda L, Tamari R, Tallman MS, Rampal RK, Zeidan AM, Stahl M. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis—A Systematic Review and Meta-Analysis. Transplantation And Cellular Therapy 2021, 27: 873.e1-873.e13. PMID: 34052505, PMCID: PMC8478722, DOI: 10.1016/j.jtct.2021.05.016.Peer-Reviewed Original ResearchConceptsConditioning regimen intensityAllo-HCTRegimen intensityChronic graftTransplant characteristicsGraft failureOverall survivalPatient ageSubgroup analysisDynamic International Prognostic Scoring System scoresSystematic reviewAllogeneic hematopoietic cell transplantationInternational Prognostic Scoring System scoreCurative therapeutic modalityNon-relapse mortalityTransplant-related mortalityMedian patient ageOutcomes of patientsSecondary graft failureCo-primary outcomesHematopoietic cell transplantHematopoietic cell transplantationRandomized clinical trialsHeterogeneity of patientsRandom-effects model
2020
Allogeneic Hematopoietic Cell Transplantation (allo-HCT) in T-Cell Prolymphocytic Leukemia (T-PLL): An Analysis from the CIBMTR
Murthy H, Ahn K, Estrada-Merly N, Gowda L, Dholaria B, Bal S, Alkhateeb H, Jagadeesh D, Oran B, Nakamura R, Scott B, Sauter C, Foss F, kharfan-Dabaja M, Saber W. Allogeneic Hematopoietic Cell Transplantation (allo-HCT) in T-Cell Prolymphocytic Leukemia (T-PLL): An Analysis from the CIBMTR. Blood 2020, 136: 28-29. DOI: 10.1182/blood-2020-134793.Peer-Reviewed Original ResearchTreatment-related mortalityDisease-free survivalT-cell prolymphocytic leukemiaConditioning intensityLess treatment-related mortalityPoor long-term survivalNon-relapse mortalityPoor performance statusRetrospective multicenter studyHematopoietic cell transplantationOverall survival rateSmall retrospective seriesLimited treatment optionsMarrow Transplant ResearchAnalysis of patientsLong-term survivalRate of survivalAcute GVHDAllo-HCTChronic graftChronic GVHDNMA/Regimen intensityDurable remissionsHost disease